Canadian drug user fees for product applications become effective Sept. 1.
This article was originally published in The Tan Sheet
Executive Summary
CANADIAN DRUG USER FEE SYSTEM WILL BE EFFECTIVE SEPT. 1 for premarket approval submission evaluations. Slated for publication in Part II of the Canada Gazette the week of Aug. 28, the "cost recovery" final regulation outlines fees that must be paid by prescription and nonprescription drug manufacturers for the review of drug-related submissions by the Canadian Health Protection Branch (HPB). The submissions evaluation fees are expected to bring in $25 mil. a year for HPB.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning